For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway. Today, the FDA approved CSL’s garadacimab-gxii ...

Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

SAN ANTONIO -- Among patients with hereditary angioedema (HAE), monthly injections of the investigational biologic garadacimab reduced the mean attack rate substantially in the phase III VANGUARD ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Haemonetics (HAE) has been beaten down lately with too much selling pressure. While the stock has lost 5.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold ...

Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...